Monitor zoci Phase 3 DLLEVATE interim analysis in H2 2027 and the epNEC topline data in H1 2027 for U.S. BLA potential. The $250M capital raise extends runway through key pipeline catalysts but adds ~10% dilution. Watch for Q4 2026 revenue trajectory as KarXT ramps and competitive dynamics for ZEJULA and OPTUNE evolve.
Drugs in focus
ZLAB drug pipeline →KarXT
● Neutral Named in this 8-K- Impact
- Phase
- Approved
- Time to market
- Already approved and commercially available in both the US (since September 2024) and China (since June 2026).
- Next catalyst
- None dated
What to watchKarXT is already approved and launching in China, so the next stock-moving events for Zai Lab around this drug are commercial milestones: NRDL (national reimbursement) negotiation outcomes, quarterly sales growth trends, and any label expansion for Alzheimer's psychosis or bipolar mania that Zai Lab might pursue in China. The next major binary catalyst for Zai Lab overall is the November 30, 2026 PDUFA date for povetacicept in IgAN, not KarXT.
How the stock moved after the report
⚠ Clustered NEUTRAL VIEWSTOCK ABOVE ENTRY AT T+5- T+0 · Nov 5 $22.60entry
- T+1 · 11d ago +12.74%α +12.43% · $25.48
- T+5 · 5d ago +15.22%α +11.93% · $26.04
- T+7 · todayOpen
- T+20 · in 17d Pending
- T+60 · in 3mo Pending
Price Chart
How similar events traded
Executive Summary
Zai Lab reported Q3 2026 total revenue of $108.2M, down 7% YoY from $116.1M, and a GAAP net loss of $46.1M ($0.41 per ADS) versus a $36.0M loss a year ago. The revenue decline was driven by competitive pressure on ZEJULA and OPTUNE, partially offset by growth in NUZYRA and the new KarXT launch. The company highlighted strong zoci (DLL3 ADC) 1L SCLC data at ESMO (81.8% ORR) and plans for a global Phase 3 study, plus a $250M private placement closed in October 2026 to fund pipeline development.
Key Financial Metrics
Key Facts
- Total revenue $108.2M in Q3 2026, down 7% YoY from $116.1M
- Product revenue net $107.6M, down 7% YoY from $115.4M; up 2% sequentially from Q2 2026
- GAAP net loss $46.1M ($0.41/ADS) vs $36.0M ($0.33/ADS) in Q3 2025; increase primarily due to $13.6M inventory write-downs
- Cash, restricted cash and short-term investments $659.7M as of Sep 30, 2026, down from $717.5M as of Jun 30, 2026
- Closed $250M private placement on Oct 27, 2026 (11.34M ADS at $22.04/ADS), net proceeds ~$241.2M
- Zoci (DLL3 ADC) 1L ES-SCLC data at ESMO: 81.8% confirmed ORR, 81.9% estimated 6-month PFS rate at 1.6 mg/kg + atezolizumab; advancing to global Phase 3
- Completed enrollment in zoci 2L+ epNEC expansion cohort; topline data expected H1 2027 with potential U.S. accelerated approval submission
- ZL-1503 (IL-13/IL-31R) first-in-human data to be presented at ACAAI Nov 2026; AD patient data expected H1 2027
- argenx discontinued Phase 3 UNITY study of efgartigimod in Sjögren's disease for futility; no impact on Zai Lab's existing approvals
- No financial guidance provided in the release
Financial Impact
Revenue declined $7.9M YoY; net loss widened by $10.1M; cash burn of $57.8M in Q3; $250M private placement completed post-quarter
Risk Factors
- Revenue continued to decline YoY for the third consecutive quarter, driven by ZEJULA generic competition and OPTUNE market share loss
- Net loss widened to $46.1M from $36.0M, with $13.6M in inventory write-downs
- argenx discontinued the Sjögren's disease Phase 3 study for futility, removing a potential future indication for efgartigimod
- Cash burn rate of ~$58M per quarter suggests ~11 quarters of runway without additional financing or revenue growth
Market Snapshot
Investment Themes
Documents Analyzed
This report is based on 6 SEC documents filed with EDGAR.
| Document | Accession Number |
|---|---|
| 8-K Filing (Primary) | 0001628280-26-070517 |
| Document: zlab-20261105.htm | 0001628280-26-070517 |
| Document: 0001628280-26-070517-index-headers.html | 0001628280-26-070517 |
| Document: 0001628280-26-070517-index.html | 0001628280-26-070517 |
| Document: 0001628280-26-070517.txt | 0001628280-26-070517 |
| 8-K Data (Synthetic) | 0001628280-26-070517 |
Track record
23 reports on ZLAB
3 of 4 bullish or bearish reports moved the stock their way by T+1. Best: +13.13% at T+20 after the May 7, 2026 report. 4 of 4 went positive at some point.
Filters
- Nov 16, 2026today SC 13G/A Neutral 3/10 Entry price pending
- Nov 5, 202611d ago 8-K Neutral 5/10 Viewing Entry $22.60 to $25.48 Now $23.47 +3.85% ▲ +12.74% +12.43% vs SPY
- Oct 23, 202624d ago 8-K Bullish 6/10 Entry $24.03 to $24.34 Now $23.47 −2.33% ▲ +1.29% +0.58% vs SPY
- Aug 21, 202612w ago Insider Cluster Neutral 2/10 Entry $25.64 to $26.17 Now $23.47 −8.46% ▲ +2.07% +1.75% vs SPY
- Aug 13, 202613w ago Insider Cluster Neutral 2/10 Entry $25.90 to $25.64 Now $23.47 −9.38% ▼ −1.00% −0.53% vs SPY
- Aug 13, 202613w ago Insider Cluster Neutral 2/10 Entry $25.90 to $25.64 Now $23.47 −9.38% ▼ −1.00% −0.53% vs SPY
- Aug 12, 202613w ago 144 Neutral 2/10 Entry $25.49 to $26.03 Now $23.47 −7.92% ▲ +2.12% +1.42% vs SPY
- Jul 1, 202619w ago Insider Cluster Neutral 2/10 Entry $19.12 to $19.08 Now $23.47 +22.75% ▼ −0.21% −1.08% vs SPY
- Jun 29, 202620w ago Insider Cluster Neutral 3/10 Entry $19.00 to $19.15 Now $23.47 +23.53% ▲ +0.79% +0.92% vs SPY
- Jun 11, 202622w ago Institutional Cluster Bearish 5/10 Entry $17.64 to $17.07 Now $23.47 −33.05% ▲ +3.23% +3.77% vs SPY
US Market Status
Subscribe to SecBot
Get Real-Time SEC Filing Intelligence
Comprehensive SEC filing analysis delivered the moment filings hit EDGAR. Sentiment scoring, impact analysis, and actionable insights for every material event.
Create a free account Live analysis, Telegram alerts, watchlists and the MCP server for subscribers